Anzeige
Mehr »
Mittwoch, 09.07.2025 - Börsentäglich über 12.000 News
750-Millionen-Euro-Finanzier verstärkt Forge - Sichtbares Gold befeuert Exploration
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MKPR | ISIN: FR0010425595 | Ticker-Symbol: ZVA
Tradegate
08.07.25 | 15:26
1,350 Euro
-0,44 % -0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLECTIS SA Chart 1 Jahr
5-Tage-Chart
CELLECTIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,3421,37008.07.
1,3521,37808.07.

Aktuelle News zur CELLECTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCellectis Inc.: Monthly information on share capital and company voting rights1
02.07.Cellectis files $200M mixed shelf offering2
26.06.Cellectis Reports Results from Shareholders Meeting Held on June 26, 20252
26.06.Cellectis S.A. - 6-K, Report of foreign issuer1
05.06.Cellectis Inc.: Monthly information on share capital and company voting rights5
21.05.Cellectis' Annual Shareholders General Meeting to be Held on June 26, 20257
21.05.Cellectis S.A. - 6-K, Report of foreign issuer2
CELLECTIS Aktie jetzt für 0€ handeln
12.05.Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M7
12.05.Cellectis Reports Financial Results for the First Quarter 2025678Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma...
► Artikel lesen
09.05.Cellectis Q1 2025 Earnings Preview2
07.05.Cellectis Inc.: Monthly information on share capital and company voting rights2
06.05.Cellectis to Report First Quarter Financial Results on May 12, 20251
06.05.Cellectis S.A. - 6-K, Report of foreign issuer3
28.04.Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting2
28.04.Cellectis S.A. - 6-K, Report of foreign issuer2
22.04.Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal5
07.04.Cellectis Inc.: Monthly information on share capital and company voting rights9
31.03.Cellectis S.A. - 6-K, Report of foreign issuer3
14.03.Cellectis Non-GAAP EPS of -$0.16 beats by $0.05, revenue of $33.22M beats by $23.63M11
13.03.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update249? UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1